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Abstract Increasing awareness of the importance of aber-
rant B cell regulation in autoimmunity has driven the clini-
cal development of novel B cell-directed biologic therapies
with the potential to treat a range of autoimmune disorders.
The Wrst of these drugs—rituximab, a chimeric monoclonal
antibody against the B cell-speciWc surface marker CD20—
was recently approved for treating rheumatoid arthritis in
patients with an inadequate response to other biologic ther-
apies. The aim of this review is to discuss the potential use
of rituximab in the management of other autoimmune dis-
orders. Results from early phase clinical trials indicate that
rituximab may provide clinical beneWt in systemic lupus
erythematosus, Sjögren’s syndrome, vasculitis, and throm-
bocytopenic purpura. Numerous case reports and several
small pilot studies have also been published reporting the
use of rituximab in conditions such as myositis, antiphosp-
holipid syndrome, Still’s disease, and multiple sclerosis. In
general, the results from these preliminary studies encour-
age further testing of rituximab therapy in formalized clini-
cal trials. Based on results published to date, it is concluded
that rituximab, together with other B cell-directed therapies
currently under clinical development, is likely to provide an
important new treatment option for a number of these diY-
cult-to-treat autoimmune disorders.
Keywords Biologic therapies · B-lymphocytes · 
CD20 · Lupus · Rituximab · Sjögren’s syndrome · 
Thrombocytopenic purpura · Vasculitis
Background
Autoimmunity is widely believed to be fundamental to the
development and progression of many rheumatic dis-
eases—rheumatoid arthritis (RA) and systemic lupus eryth-
ematosus (SLE) being the best-known examples. The
function of B cells in autoimmunity is still not fully under-
stood, although evidence is mounting that they play an
essential role in the process. In addition to their well-known
function in synthesizing antibodies, B cells act in antigen
presentation and as critical regulators of the development
and function of T cells [21]. B cells are also the source of
rheumatoid factor, levels of which are strongly correlated
with disease severity in RA [103]. These and other lines of
evidence provided the rationale for testing whether B cell
depletion would be an eVective strategy for treating rheu-
matic diseases. The availability of rituximab (RITUXAN®;
Genentech/Biogen-IDEC, South San Francisco, CA, USA),
a genetically engineered monoclonal antibody directed
against the B cell-speciWc antigen CD20 [60], enabled this
hypothesis to be tested. The Wrst results, demonstrating sus-
tained clinical responses coupled with B cell depletion in 5
RA patients treated with rituximab [30], ignited intense
interest in the wider potential of B cell depletion therapy in
autoimmune diseases.
A full-scale clinical trial program led to the approval of
rituximab in 2006 for the treatment of RA in patients with
an inadequate response to anti-tumour necrosis factor
(TNF) therapy. A number of other B cell-directed agents
are currently in clinical development. Among the most
advanced is epratuzumab, a humanized monoclonal anti-
body directed against CD22, another B cell-speciWc marker
[90]. Epratuzumab has been tested in patients with Sjö-
gren’s syndrome (SS) [89] and results were published
recently of an open-label clinical trial involving patients
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with SLE [29]. Another strategy under investigation is the
neutralization of B cell survival factors. BAFF (also known
as B lymphocyte stimulator, BLyS) is essential for the sur-
vival of B cells and is involved in many other aspects of B
cell biology, including germinal center maintenance, iso-
type switching, and regulation of B cell-speciWc markers
[48]. Belimumab is an anti-BAFF monoclonal antibody
that has reached Phase II trials in SLE and RA [27], while
atacicept (previously known as TACI-Ig), a recombinant
fusion protein that neutralizes both BAFF and APRIL (a
related B cell survival factor) [41], has undergone Phase I
evaluation in SLE. A more in-depth review was published
recently of current B cell-targeted approaches that are being
developed to treat autoimmune disorders [31].
The aim of this review is to discuss the potential utility
of B cell-directed therapy in the management of autoim-
mune disorders. As the Wrst of these agents to be approved
for clinical use, rituximab will be the focus of this article. In
addition, since several excellent reviews have been pub-
lished recently covering the use of rituximab in RA [25, 31,
58], this review will discuss results from the clinical testing
of rituximab in autoimmune disorders other than RA. Infor-
mation from case reports, clinical trials, and other studies
was gathered from a search of the Medline database up to
and including June 2007.
Clinical use of rituximab
Rituximab has been tested in a wide range of autoimmune
conditions, with clinical trials being most advanced in SLE
and SS. A summary of the published clinical data in these
and other autoimmune disorders is presented in Table 1.
Systemic lupus erythematosus
Traditional treatments for SLE include nonsteroidal anti-
inXammatory drugs, antimalarials, corticosteroids, metho-
trexate, mycophenylate, and cytotoxic drugs such as cyclo-
phosphamide (often in combination). However, these
therapies are associated with many potential side eVects
and are usually only partially eVective in the long term
[46]. The wide body of evidence indicating that B cells play
a central role in the etiopathology of SLE has focused atten-
tion on the potential beneWts of rituximab and other B cell-
targeted therapies in the disease [33, 57, 78].
Individual case reports and case series, together with
encouraging results from early phase clinical trials, indicate
that rituximab is likely to provide signiWcant clinical beneWt
for at least a subset of SLE patients. For example, in a dose-
escalation study involving 17 patients, signiWcant improve-
ments in the systemic lupus activity measure (SLAM) score
were observed in those patients (11/17) who achieved con-
comitant profound B cell depletion; eYcacy persisted for
12 months and no signiWcant adverse events were reported
[59]. Analysis of some of the patients in this trial revealed that
clinical response to rituximab correlated closely with the FcI-
IIa genotype of individual patients [6], as observed previously
in studies involving the rituximab responses of patients with
follicular lymphoma [96]. In another open-label study, 23/24
patients achieved depletion of B cells following treatment
with rituximab (two 1,000 mg infusions of rituximab sepa-
rated by 2 weeks); depletion lasted for 3–8 months—except in
1 individual, who remained depleted after 4 years [55]. Clini-
cal improvements observed in this study occurred in each of
the 8 organs/systems assessed using the British Isles Lupus
Assessment Group (BILAG) system. A recent update from
the same group—covering a total of 41 patients with a mean
(range) follow-up period of 37 (6–79) months—reported that
one-third of patients remained well following B cell deple-
tion, without the need for immunosuppressive agents [64].
Thirteen patients had been re-treated with rituximab. Three
serious adverse events (1 pneumococcal sepsis, 1 severe
serum sickness-like reaction, and 1 seizure related to hypona-
tremia) and 2 deaths (1 involving varicella pneumonitis and
the other involving pancarditis) had occurred in this cohort
over the 7-year observation period.
In another trial involving patients with active or refrac-
tory SLE, with a follow-up period of 2 years, all 11 patients
in the study responded to a single course of rituximab, with
6 achieving a full response and 5 a partial response;
although relapse was common (64%), re-treatment was rap-
idly eVective [85].
In a recently reported case series of six patients with
aggressive refractory SLE, rituximab therapy (doses of rit-
uximab and use of combination drugs varied between
patients) resulted in partial clinical improvements in Wve
cases [40]. Rituximab has also shown eVectiveness in pilot
studies involving patients with the common severe compli-
cation lupus nephritis [42,  84,  95] and in patients with
refractory SLE involving the central nervous system [92].
Although most studies to date indicate that B cell deple-
tion therapy is likely to be useful in SLE, the variability of
responses to rituximab therapy observed in SLE trials pub-
lished to date remains to be explained. Ongoing Phase II/III
randomized controlled trials should provide some insight
into this question. In addition, although the overall tolera-
bility of rituximab in SLE appears to be good, the Food and
Drug Administration recently issued an alert concerning
two spontaneous fatal cases of progressive multifocal leu-
koencephalopathy (PML) due to JC polyomavirus reactiva-
tion in two patients with SLE who had received rituximab
therapy [38]. It is unclear whether these cases were related
to rituximab treatment, since only two cases have been
reported and PML has also been reported in >20 SLE
patients not treated with rituximab.Rheumatol Int (2008) 28:205–215 207
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6
m
o
n
t
h
s
C
a
s
e
 
s
e
r
i
e
s
 
[
8
8
]
1
0
e
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
w
e
e
k
l
y
 
f
o
r
 
4
w
e
e
k
s
+
p
r
e
d
n
i
s
o
n
e
 
(
·
2
m
g
/
k
g
/
d
a
y
,
 
t
a
p
e
r
i
n
g
 
o
n
c
e
 
d
i
s
e
a
s
e
 
a
c
t
i
v
i
t
y
 
i
m
p
r
o
v
e
d
)
C
o
m
p
l
e
t
e
 
r
e
s
p
o
n
s
e
 
(
B
V
A
S
/
W
G
=
0
)
 
i
n
 
9
p
t
s
 
a
n
d
 
p
a
r
t
i
a
l
 
r
e
s
p
o
n
s
e
 
(
B
V
A
S
/
W
G
=
1
)
 
i
n
 
1
p
t
 
a
t
 
6
m
o
n
t
h
s
.
 
F
o
l
l
o
w
-
u
p
 
(
m
e
d
i
a
n
 
3
4
m
o
n
t
h
s
;
 
r
a
n
g
e
 
2
6
–
4
5
m
o
n
t
h
s
)
:
 
3
p
t
s
 
r
e
l
a
p
s
e
d
 
b
u
t
 
h
a
d
 
n
e
w
 
s
u
s
t
a
i
n
e
d
 
r
e
s
p
o
n
s
e
 
f
o
l
l
o
w
i
n
g
 
r
e
-
t
r
e
a
t
m
e
n
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T
a
b
l
e
1
c
o
n
t
i
n
u
e
d
D
i
s
o
r
d
e
r
/
s
t
u
d
y
 
t
y
p
e
N
o
.
 
o
f
 
p
t
s
T
r
e
a
t
m
e
n
t
 
r
e
g
i
m
e
n
S
u
m
m
a
r
y
 
o
f
 
c
l
i
n
i
c
a
l
 
r
e
s
u
l
t
s
O
p
e
n
-
l
a
b
e
l
 
[
8
5
]
1
1
c
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
w
e
e
k
l
y
 
f
o
r
 
4
w
e
e
k
s
+
C
y
P
 
(
5
0
0
m
g
)
 
c
o
-
a
d
m
i
n
i
s
t
e
r
e
d
 
a
t
 
W
r
s
t
 
i
n
f
u
s
i
o
n
;
 
i
m
m
u
n
o
s
u
p
p
r
e
s
s
i
v
e
 
t
h
e
r
a
p
y
 
a
t
 
b
a
s
e
l
i
n
e
 
h
a
d
 
b
e
e
n
 
u
n
c
h
a
n
g
e
d
 
f
o
r
 
¸
3
m
o
n
t
h
s
 
p
r
i
o
r
 
t
o
 
s
t
u
d
y
 
a
n
d
 
w
a
s
 
c
o
n
t
i
n
u
e
d
 
u
n
t
i
l
 
M
o
n
t
h
 
6
,
 
f
o
l
l
o
w
i
n
g
 
w
h
i
c
h
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
w
a
s
 
a
l
l
o
w
e
d
R
e
m
i
s
s
i
o
n
 
i
n
 
9
/
1
1
p
t
s
 
(
B
V
A
S
=
0
)
 
a
n
d
 
p
a
r
t
i
a
l
 
r
e
m
i
s
s
i
o
n
 
i
n
 
1
p
t
 
(
B
V
A
S
=
2
)
;
 
6
/
1
0
p
t
s
 
s
u
b
s
e
q
u
e
n
t
l
y
 
r
e
l
a
p
s
e
d
 
b
u
t
 
h
a
d
 
n
e
w
 
s
u
s
t
a
i
n
e
d
 
r
e
s
p
o
n
s
e
 
f
o
l
l
o
w
i
n
g
 
r
e
-
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
R
T
X
 
(
2
£
1
0
0
0
m
g
,
 
2
w
e
e
k
s
 
a
p
a
r
t
)
C
a
s
e
 
s
e
r
i
e
s
 
[
8
]
8
d
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
e
v
e
r
y
 
4
w
e
e
k
s
 
f
o
r
 
4
 
c
y
c
l
e
s
+
s
t
a
n
d
a
r
d
 
t
r
e
a
t
m
e
n
t
 
(
C
y
P
 
2
m
g
/
k
g
 
o
n
c
e
 
d
a
i
l
y
 
o
r
 
1
5
–
2
0
m
g
/
k
g
 
e
v
e
r
y
 
1
8
–
2
1
d
a
y
s
 
o
r
 
m
e
t
h
o
t
r
e
x
a
t
e
 
0
.
3
m
g
/
k
g
 
o
n
c
e
 
w
e
e
k
l
y
)
 
R
e
m
i
s
s
i
o
n
 
(
B
V
A
S
=
0
)
 
i
n
 
2
p
t
s
,
 
p
a
r
t
i
a
l
 
r
e
m
i
s
s
i
o
n
 
i
n
 
1
p
t
,
 
u
n
c
h
a
n
g
e
d
 
d
i
s
e
a
s
e
 
a
c
t
i
v
i
t
y
 
i
n
 
3
p
t
s
,
 
a
n
d
 
p
r
o
g
r
e
s
s
i
o
n
 
i
n
 
2
p
t
s
 
1
m
o
n
t
h
 
a
f
t
e
r
 
W
n
a
l
 
c
y
c
l
e
M
y
o
s
i
t
i
s
O
p
e
n
-
l
a
b
e
l
 
p
i
l
o
t
 
[
5
6
]
7
f
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
w
e
e
k
l
y
 
f
o
r
 
4
w
e
e
k
s
+
s
t
a
n
d
a
r
d
 
t
r
e
a
t
m
e
n
t
 
(
i
n
c
l
u
d
e
d
 
a
z
a
t
h
i
o
p
r
i
n
e
,
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
,
 
C
y
P
,
 
a
n
d
 
i
n
t
r
a
v
e
n
o
u
s
i
m
m
u
n
o
g
l
o
b
u
l
i
n
)
C
l
i
n
i
c
a
l
 
i
m
p
r
o
v
e
m
e
n
t
 
(
i
n
c
r
e
a
s
e
d
 
m
u
s
c
l
e
 
s
t
r
e
n
g
t
h
 
r
e
l
a
t
i
v
e
 
t
o
 
b
a
s
e
l
i
n
e
 
[
a
s
s
e
s
s
e
d
 
u
s
i
n
g
 
d
y
n
o
m
o
m
e
t
r
y
]
)
 
i
n
 
a
l
l
 
6
 
e
v
a
l
u
a
b
l
e
 
p
t
s
 
I
d
i
o
p
a
t
h
i
c
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
 
p
u
r
p
u
r
a
O
p
e
n
-
l
a
b
e
l
 
p
i
l
o
t
 
[
8
7
]
2
5
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
w
e
e
k
l
y
 
f
o
r
 
4
w
e
e
k
s
C
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
 
(
r
i
s
e
 
i
n
 
p
l
a
t
e
l
e
t
 
c
o
u
n
t
s
)
 
a
t
 
e
n
d
 
o
f
 
t
h
e
r
a
p
y
 
w
i
t
h
o
u
t
 
n
e
e
d
 
f
o
r
 
f
u
r
t
h
e
r
 
t
r
e
a
t
m
e
n
t
 
i
n
 
1
3
/
2
5
 
(
5
2
%
)
 
p
t
s
.
 
R
e
s
p
o
n
s
e
s
 
w
e
r
e
 
s
u
s
t
a
i
n
e
d
 
f
o
r
 
¸
6
m
o
n
t
h
s
 
i
n
 
7
p
t
s
P
o
o
l
e
d
 
d
a
t
a
 
f
r
o
m
 
t
w
o
 
p
i
l
o
t
 
t
r
i
a
l
s
 
[
2
2
]
5
7
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
w
e
e
k
l
y
 
f
o
r
 
4
w
e
e
k
s
;
 
1
7
p
t
s
 
r
e
c
e
i
v
e
d
 
p
r
e
d
n
i
s
o
n
e
 
(
6
0
m
g
 
w
i
t
h
 
I
n
f
u
s
i
o
n
 
1
 
a
n
d
 
2
0
m
g
 
w
i
t
h
 
I
n
f
u
s
i
o
n
 
2
)
C
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
 
(
r
i
s
e
 
i
n
 
p
l
a
t
e
l
e
t
 
c
o
u
n
t
s
)
 
a
t
 
e
n
d
 
o
f
 
t
h
e
r
a
p
y
 
w
i
t
h
o
u
t
 
n
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o
r
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r
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t
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p
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;
 
2
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1
 
r
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s
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o
c
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r
r
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t
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e
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p
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c
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p
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r
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p
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c
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c
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c
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p
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c
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p
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p
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p
r
e
d
n
i
s
o
n
e
+
a
n
t
i
h
i
s
t
a
m
i
n
e
 
p
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r
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p
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b
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o
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c
e
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e
k
l
y
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r
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e
e
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s
 
(
n
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)
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r
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r
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e
e
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(
n
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1
2
)
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3
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p
t
s
 
r
e
c
e
i
v
e
d
 
R
T
X
 
w
i
t
h
 
o
t
h
e
r
 
t
h
e
r
a
p
i
e
s
 
(
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
[
n
=
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]
,
 
I
V
I
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[
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=
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c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
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V
I
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[
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=
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o
t
h
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[
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]
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C
l
i
n
i
c
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l
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e
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p
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p
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n
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e
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a
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n
 
(
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)
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f
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(
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–
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o
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s
,
 
1
2
p
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s
 
f
o
r
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1
2
m
o
n
t
h
s
 
T
h
r
o
m
b
o
t
i
c
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
 
p
u
r
p
u
r
a
O
p
e
n
-
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a
b
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l
 
p
r
o
s
p
e
c
t
i
v
e
 
m
u
l
t
i
c
e
n
t
e
r
 
[
3
5
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1
1
R
T
X
 
(
3
7
5
m
g
/
m
2
)
 
o
n
c
e
 
w
e
e
k
l
y
 
f
o
r
 
4
w
e
e
k
s
+
p
r
e
m
e
d
i
c
a
t
i
o
n
 
w
i
t
h
 
I
V
 
s
t
e
r
o
i
d
s
 
(
3
0
m
g
)
,
 
I
V
 
d
e
x
c
h
l
o
r
p
h
e
n
i
r
a
m
i
n
e
 
(
1
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m
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)
,
 
a
n
d
 
I
V
 
p
a
r
a
c
e
t
a
m
o
l
 
(
1
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.
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
a
c
u
t
e
 
T
T
P
 
(
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=
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)
 
c
o
n
t
i
n
u
e
d
 
p
l
a
s
m
a
 
i
n
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u
s
i
o
n
s
 
f
o
r
 
¸
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w
e
e
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s
 
f
o
l
l
o
w
e
d
 
b
y
 
t
a
p
e
r
i
n
g
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t
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h
e
 
o
n
s
e
t
 
o
f
 
r
e
m
i
s
s
i
o
n
C
l
i
n
i
c
a
l
 
r
e
m
i
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i
o
n
 
(
r
e
g
r
e
s
s
i
o
n
 
o
f
 
v
i
s
c
e
r
a
l
 
i
s
c
h
e
m
i
c
 
s
i
g
n
s
 
a
n
d
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
o
f
 
b
l
o
o
d
 
p
a
r
a
m
e
t
e
r
s
)
 
i
n
 
a
l
l
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
a
c
u
t
e
 
T
T
P
;
 
c
o
n
t
i
n
u
e
d
 
r
e
m
i
s
s
i
o
n
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
d
i
s
e
a
s
e
 
r
e
m
i
s
s
i
o
n
 
a
t
 
e
n
r
o
l
m
e
n
t
 
(
6
–
1
1
m
o
n
t
h
s
’
 
f
o
l
l
o
w
-
u
p
)
.
 
B
i
o
l
o
g
i
c
 
r
e
m
i
s
s
i
o
n
 
(
¸
1
0
%
 
r
e
c
o
v
e
r
y
 
o
f
 
A
D
A
M
T
S
-
1
3
 
a
c
t
i
v
i
t
y
 
a
n
d
 
d
i
s
a
p
p
e
a
r
a
n
c
e
 
o
f
 
a
n
t
i
-
A
D
A
M
T
S
-
1
3
 
a
n
t
i
b
o
d
i
e
s
)
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l
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T
a
b
l
e
1
c
o
n
t
i
n
u
e
d
a
P
r
o
l
i
f
e
r
a
t
i
v
e
 
l
u
p
u
s
 
n
e
p
h
r
i
t
i
s
,
 
b
A
N
C
A
-
p
o
s
i
t
i
v
e
 
m
i
c
r
o
s
c
o
p
i
c
 
p
o
l
y
a
n
g
i
t
i
s
 
(
n
=
2
)
 
a
n
d
 
A
N
C
A
-
p
o
s
i
t
i
v
e
 
W
e
g
e
n
e
r
’
s
 
g
r
a
n
u
l
o
m
a
t
o
s
i
s
 
(
n
=
7
)
,
 
c
A
N
C
A
-
a
s
s
o
c
i
a
t
e
d
 
v
a
s
c
u
l
i
t
i
s
d
A
N
C
A
-
p
o
s
i
t
i
v
e
 
r
e
f
r
a
c
t
o
r
y
 
W
e
g
e
n
e
r
’
s
 
g
r
a
n
u
l
o
m
a
t
o
s
i
s
,
 
e
A
N
C
A
-
p
o
s
i
t
i
v
e
 
m
i
c
r
o
s
c
o
p
i
c
 
p
o
l
y
a
n
g
i
t
i
s
 
(
n
=
2
)
 
a
n
d
 
A
N
C
A
-
p
o
s
i
t
i
v
e
 
W
e
g
e
n
e
r
’
s
 
g
r
a
n
u
l
o
m
a
t
o
s
i
s
 
(
n
=
8
)
,
 
f
D
e
r
m
a
t
o
m
y
o
s
i
t
i
s
,
 
g
C
l
i
n
i
c
a
l
r
e
s
u
l
t
s
 
w
e
r
e
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
p
h
y
s
i
c
i
a
n
s
 
v
i
a
 
a
 
q
u
e
s
t
i
o
n
n
a
i
r
e
 
(
o
r
i
g
i
n
a
l
 
p
a
t
i
e
n
t
 
d
a
t
a
 
w
e
r
e
 
n
o
t
 
a
n
a
l
y
z
e
d
)
,
 
h
H
C
V
-
p
o
s
i
t
i
v
e
 
t
y
p
e
 
I
I
 
o
r
 
t
y
p
e
 
I
I
I
 
m
i
x
e
d
 
c
r
y
o
g
l
o
b
u
l
i
n
e
m
i
a
,
 
i
T
y
p
e
 
I
I
 
m
i
x
e
d
 
c
r
y
o
g
l
o
b
u
l
i
n
e
m
i
a
(
H
C
V
-
p
o
s
i
t
i
v
e
 
[
n
=
1
2
]
;
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
S
S
 
[
n
=
1
]
;
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Sjögren’s syndrome
Sjögren’s syndrome is a chronic autoimmune disorder of
the exocrine glands aVecting approximately 1% of the adult
US population. The syndrome often occurs in the presence
of another autoimmune disorder such as RA or SLE [37].
The etiopathology of SS is not fully understood; however,
disturbances in B cell biology are considered to play an
important role [43].
A number of case reports and pilot studies have been
published that describe the successful treatment of SS with
rituximab [2,  73,  76,  93]. In a recent trial involving 16
female patients with systemic complications of primary SS,
rituximab therapy led to B cell depletion and decreased lev-
els of various B cell markers; with a median follow-up
period of 14.5 months, clinical eYcacy was observed in 4/5
patients with lymphomas and in 9/11 patients with other
systemic manifestations [83].
Another recent study investigated the eVects of ritux-
imab (two infusions of 375 mg/m2 separated by 1 week) in
16 patients with primary SS [26]. Rituximab therapy, which
was administered using a slow initial rate of infusion with-
out steroid premedication, was well tolerated and overall
improvements were observed in subjective parameters of
disease activity and in quality of life after both 12 and
36 weeks’ follow-up.
Results were presented recently from the Wrst double-
blind, randomized, controlled study of rituximab in SS
[24]. In this 20-patient pilot study, subjects received either
rituximab (two 1,000 mg infusions separated by 2 weeks)
or placebo. Although patient responses were highly vari-
able and there was a marked placebo eVect, a higher pro-
portion of patients in the rituximab group achieved
improvement in fatigue (the primary eYcacy endpoint)
than in the placebo group (48 vs. 20%); this diVerence was
not statistically signiWcant. SigniWcantly greater improve-
ments with rituximab over placebo in the social functioning
aspect of the quality of life assessment were also noted.
Vasculitis
Vasculitis refers to a collection of rare inXammatory dis-
eases that involve the blood vessel walls and surrounding
interstitium. A subset of these diseases, including
Wegener’s granulomatosis (WG), microscopic polyangitis,
and Churg–Strauss syndrome, is characterized by the pres-
ence of anti-neutrophil cytoplasmic antibodies (ANCAs)
[97]. The mainstay of current therapies in vasculitis
involves glucocorticoids, cyclophosphamide, and—more
recently—methotrexate and azathioprine [54]. However,
these approaches are not always eVective and are often lim-
ited by signiWcant toxicity. B cells have been implicated in
the pathogenesis of ANCA-associated vasculitis [20], indi-
cating that rituximab may be an eVective treatment option.
In addition to a number of individual case reports, results
have been published recently from several small open-label
trials of rituximab in vasculitis. In a report of a series of
nine individual cases of ANCA-positive vasculitis resistant
to conventional therapy in which rituximab therapy was
attempted, eight patients achieved complete responses,
while the other patient showed a partial response [34].
Keogh and colleagues have conducted small, prospective,
open-label trials in both ANCA-associated vasculitis and
WG. The vasculitis trial involved 11 patients whose disease
was either refractory to cyclophosphamide or in whom
cyclophosphamide was contraindicated [50]. Following
infusions with rituximab, circulating B cells became unde-
tectable in all patients and ANCA titers decreased signiW-
cantly. Clinical remission was achieved in all patients and
was maintained while B cells were undetectable. In ten
patients with refractory WG treated with prednisone (1 mg/
kg/day) plus rituximab (four consecutive weekly infusions
of 375 mg/m2) [51], therapy was well tolerated and—after
3 months—all patients had achieved clinical remission
(reduction in disease activity score to 0); in addition, all
patients were able to stop glucocorticoids by 6 months. Fol-
lowing the recurrence of raised ANCA titers, Wve patients
in the trial were successfully re-treated with rituximab.
Results were also recently published of long-term follow-
up of ten patients with ANCA-associated vasculitis who
had been treated with rituximab [88]: patients had received
four consecutive weekly doses of rituximab (375 mg/m2)
and all experienced rapid clinical improvement at
6 months. Although three patients subsequently relapsed,
re-treatment was eVective. In addition, ANCA titers
decreased signiWcantly in all patients. Of 11 patients with
refractory ANCA-associated vasculitis who were treated
with rituximab in another recently published pilot study, 10
showed either complete or partial responses to a course of
rituximab together with a single dose of cyclophosphamide
[85].
In contrast to the above Wndings, one recent study found
that rituximab was less eVective in a cohort of eight patients
with refractory WG [8]. In this trial, rituximab was given
every fourth week. Interestingly, all patients in this study
had particular granulomatous manifestations, consisting of
retro-orbital granulomata (n = 5), nodules of the lungs
(n = 1), and subglottic stenosis (n = 2). Although three
patients experienced some clinical improvement, ANCA
titers were not aVected by rituximab therapy (except in a
single patient). A smaller Norwegian study had also previ-
ously found only temporary responses to rituximab in three
patients with WG, two of whom had granulomatous masses
[68].Rheumatol Int (2008) 28:205–215 211
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In a recent review of published studies in this area, it was
concluded that rituximab may be an eVective treatment in
patients with refractory ANCA-associated vasculitis (with
the probable exception of WG patients with retro-orbital
granulomas, who tended to be less responsive to rituximab
therapy) [98]. Since then, however, case reports have
appeared describing the successful use of rituximab in
patients with granulomatous involvement [79, 91]. In addi-
tion, results from a recent case series of eight WG patients
indicated that, while vasculitis symptoms tended to disap-
pear relatively quickly, granulomatous manifestations usu-
ally regressed more slowly (sometimes over several
months) [14].
With regard to other forms of ANCA-associated vasculi-
tis, two individual case reports have been published
recently detailing the successful treatment of Churg–
Strauss syndrome with rituximab [49, 52].
Thrombocytopenic purpura and other hematologic 
disorders
A number of autoimmune disorders of hemostasis, most
notably idiopathic thrombocytopenic purpura (ITP) and
thrombotic thrombocytopenic purpura (TTP), have been
examined for their potential responsiveness to rituximab in
several small trials.
In a study involving a cohort of 25 patients with chronic
ITP that had proved resistant to conventional therapies [87],
patients received weekly rituximab at a dose of 375 mg/m2
for 4 weeks. The overall response rate (comprising those
with complete, partial, and minor responses) was 52%;
responses were sustained for at least 6 months in 7 patients.
Complete and partial responses were associated with rapid
normalization of platelet concentrations. A similar initial
response rate (54%) was reported from a larger follow-up
trial involving 57 patients; sustained responses were
observed in 32% of the study participants [22]. Other
reports include a multicenter trial in 35 adults with refrac-
tory ITP conducted in Denmark, which resulted in a 44%
overall success rate based on predeWned rises in platelet
concentrations [13]. An indirect retrospective survey of
Wndings from 89 ITP patients treated at multiple centers in
Spain indicated that rituximab therapy led to sustained
responses in 35% of patients with a median follow-up of
9 months (range 2–42 months) [71].
A review was published recently of the clinical out-
comes of patients with chronic ITP who were re-treated
with rituximab following an initial response to therapy
[72]. All 9 second responses recorded in this report were
classiWed as complete. An interesting additional Wnding
was the higher female:male ratio of the nine re-treated
patients compared with the population of patients originally
treated across the published studies identiWed, suggesting
that female ITP patients are more likely than male patients
to respond to rituximab therapy. In a recently published let-
ter, early administration of rituximab was reported to be
associated with a higher response rate in chronic ITP [102].
The eYcacy and safety of rituximab in adults with ITP
were the subject of a recently published systematic review
[9]. Based on 19 reports (313 patients) deemed eligible for
the analysis up to April 2006, rituximab therapy was asso-
ciated with mean complete response (platelet count
>150 £ 109 cells/l) and overall response (platelet count
>50 £ 109 cells/l) rates of 44 and 63%, respectively. Sig-
niWcant toxicities including death occurred in 3% of
included cases, although the deaths were not necessarily
attributable to rituximab therapy. The authors noted the
lack of randomized controlled studies of rituximab therapy
in ITP.
A number of studies have also been conducted in
patients with refractory or relapsing TTP. In addition to
several case reports and small case series [3, 17, 69, 70, 74,
99], results from the Wrst prospective trial have been pub-
lished [35]. This study recruited 11 patients (6 enrolled dur-
ing an acute refractory phase and 5 during a remission
phase); following rituximab therapy (375 mg/m2 once
weekly for 4 weeks), clinical remission was observed in all
6 acute cases, while all 5 patients enrolled during remission
remained in clinical remission during the 6–11 month fol-
low-up period. Biologic remission (disappearance of anti-
ADAMTS-13 [a disintegrin and metalloproteinase with
thrombospondin motif 13] antibodies, which occur in the
great majority of patients with acquired TTP [75]) was
achieved in all patients 7–24 weeks after the Wnal rituximab
infusion.
Another more recent study involved 25 patients with
acute refractory/relapsing idiopathic TTP, who were given
rituximab in conjunction with plasma exchange (PEX)
because of progressive clinical disease [82]. It was reported
that all 25 patients in this trial achieved complete clinical
and laboratory remission (sustained normal platelet count,
absence of clinical manifestations of TTP, and cessation of
PEX) in a median of 11 days following the initiation of rit-
uximab therapy. Restoration of ADAMTS-13 activity and
disappearance of anti-ADAMTS antibodies occurred in the
vast majority of cases. At the time of publication, it was
stated that none of the patients had clinically relapsed, with
a median (range) follow-up of 10 (1–33) months.
In another recent retrospective study, the clinical out-
come of patients who had received rituximab (375 mg/m2
once weekly for a maximum of 8 weeks) together with
standard therapy (PEX + corticosteroids) was compared
with that of patients who had received standard therapy
alone [45]. The remission rate in the rituximab group was
signiWcantly greater than that observed in the standard ther-
apy group (100 vs. 66%; P = 0.0025). Interestingly, all212 Rheumatol Int (2008) 28:205–215
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three of the TTP studies described above reported good tol-
erability to rituximab therapy.
There have also been sporadic case reports describing the
successful use of rituximab in a number of other rare hema-
tologic disorders, including Evans’ syndrome [61,  65],
mixed type II cryoglobulinemia [15,  80,  101], and cold
agglutinin disease [11, 81]. In addition, we have recently
reported on the successful use of rituximab in RA patients
with life-threatening hemorrhage due to the presence of Fac-
tor VIII inhibitor [67]. By contrast, a case report describing
the failure of rituximab therapy in a hemophiliac patient
with Factor VIII inhibitor has also been published [18]. A
recent analysis of published case reports of patients with
acquired antibodies to Factor VIII indicated that rituximab
therapy was associated with a similar rate of clinical remis-
sion (approximately 80%) compared with the standard treat-
ment modality (cyclophosphamide + prednisolone) [86].
Myositis
Myositis comprises a group of inXammatory myopathies, of
which polymyositis, dermatomyositis, and inclusion body
myositis are the best deWned clinically. The etiopathologies
of this group of diseases are currently poorly understood,
although autoimmunity is thought to play an important role
[19].
The aim of a recent open-label pilot study involving
seven patients with dermatomyositis was to test the hypoth-
esis that B cells play a critical role in this disease [56]. The
results of this trial, in which patients received four infu-
sions of rituximab (375 mg/m2) at weekly intervals, showed
that rituximab therapy was well tolerated and led to signiW-
cant clinical improvements in the six evaluable patients
who completed 1 year of follow-up. A number of other
small pilot studies and case reports have also appeared
recently detailing the generally successful use of rituximab
in patients with dermatomyositis or polymyositis [7, 12, 16,
28, 53, 62, 66].
Antiphospholipid syndrome
Antiphospholipid syndrome (APS), a rare disorder mostly
aVecting young adults, is deWned by the presence of autoan-
tibodies against phospholipids; the main clinical manifesta-
tions are venous or arterial thrombosis and obstetric
complications, although the link between antiphospholipid
antibodies and these clinical features has not been Wrmly
established [39]. The traditional approach to treatment
mainly involves the use of anticoagulation therapies. How-
ever, data indicating a link between raised circulating
CD5+ B cells and high levels of antiphospholipid antibod-
ies in APS patients [100] suggest that APS may be amena-
ble to B cell-directed therapies.
To date, only a small number of case reports have been
published which detail attempts to manage APS with ritux-
imab. Three of these studies [5, 77, 94] reported successful
clinical outcomes following rituximab therapy, while the
other [4] reported only a limited eVect of rituximab on
thrombocytopenia and anticardiolipin antibodies in a
patient with primary APS. Although the data are currently
limited, the striking clinical successes seen in some patients
suggest that pilot studies with rituximab in APS should be
conducted in the near future.
Still’s disease
Adult-onset Still’s disease (AOSD) is a systemic inXamma-
tory disorder of unknown etiology. Traditional therapies
include NSAIDs, corticosteroids, and—more recently—
disease-modifying anti-rheumatic drugs [47]. A number of
trials have also been conducted with biologic agents
(including TNF inhibitors), with some promising results
[32].
One case report was published recently that described
the successful use of rituximab in a patient with AOSD [1].
This report, together with the author’s unpublished obser-
vations of two patients with AOSD refractory to cytotoxic
agents who beneWted from repeated rituximab infusion
therapy, suggests that rituximab may be a future treatment
option for this disease.
Neurologic disorders
As reviewed recently by Finsterer [36], rituximab has been
tested in a number of immune-mediated peripheral neurop-
athies with promising results. Its potential clinical utility in
neurological diseases of the central nervous system such as
multiple sclerosis (MS) remains to be explored. Encourag-
ingly, pilot studies have shown that rituximab therapy
results in partial depletion of B cells from the cerebrospinal
Xuid of patients with progressive MS [23, 63]. The results
of the Wrst Phase I and II trials of rituximab in progressive
MS were presented recently [10, 44]. In the placebo-con-
trolled Phase II study [44], involving 104 patients with
relapsing remitting MS, a single course of rituximab (two
infusions of 1,000 mg given 2 weeks apart) resulted in sig-
niWcantly fewer inXammatory brain lesions and relapses
over the 6-month observation period compared with pla-
cebo. Rituximab treatment was reported to have been well
tolerated.
Conclusions
Recent advances in our understanding of autoimmunity
have opened up new avenues for exploring novel targetedRheumatol Int (2008) 28:205–215 213
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therapies in a wide range of diseases. The role of B cells in
many autoimmune disorders is now widely accepted, in
many cases through the demonstration that B cell depletion
using rituximab can often be very eVective clinically. The
potential utility of rituximab and other B cell-directed ther-
apies is currently being studied in several of these diseases,
including SLE, SS, and vasculitis. Although to date most of
the Wndings have been encouraging, a signiWcant proportion
of the information derives from case reports and small case
series. Together with the lack of randomized controlled tri-
als in most of the diseases discussed in this review, it is
likely that there has been a degree of positive reporting
bias. Therefore, until large-scale clinical trial data are avail-
able, it would be prudent to proceed with caution regarding
the use of rituximab outside its approved indications.
Although rituximab tolerability was generally reported as
favorable in most of the studies covered in this review, the
true incidence of associated adverse events (e.g., serious
infections, serum sickness-like reactions, and PML) will
only become clear when larger numbers of patients have
been treated in each disease entity. Important questions also
remain regarding the optimal rituximab dosing modalities
for each disease (for example, the dose and frequency of
treatment, when re-treatment should be considered, and
whether to use combination therapies). Nevertheless, based
on the information published to date, it seems likely that B
cell depletion therapy, using rituximab and—in the
future—agents currently under development, will oVer an
eVective new approach for the management of many of
these burdensome and diYcult-to-treat conditions.
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